TRAF4 depletion overcomes radioresistant both in vitro and in vivo, suggesting that TRAF4 is a potential marker to predict radiosensitivity and a potential therapeutic target for NPC treatment. This evidence concerns the gene TRAF4 and nasopharyngeal carcinoma.